Elucidating the Role of Pro-renin Receptors in Pancreatic Ductal Adenocarcinoma Progression: A Novel Therapeutic Target in Cancer Therapy

Title:Elucidating the Role of Pro-renin Receptors in Pancreatic Ductal Adenocarcinoma Progression: A Novel Therapeutic Target in Cancer Therapy

Volume: 24

Author(s): Mohsen Aliakbarian, Gordon A. Ferns, Mahmoud Mohamadzadeh Shabestari, Amir Mahmoud Ahmadzadeh, Aref Abdollahzade, Hoda Rahimi, Rozita Khodashahi and Mohammad-Hassan Arjmand*

Affiliation:

• Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Keywords: Renin-angiotensin system, pro-renin receptor, pancreatic ductal adenocarcinoma, target therapy, molecular signaling pathways.

Abstract: Pancreatic cancer is a highly aggressive malignancy with a very poor prognosis. The 5- year survival in these patients is very low, and most patients develop drug resistance to current therapies, so additional studies are needed to identify the potential role of new drug targets for the treatment of pancreatic cancer. Recent investigations have been performed regarding the roles of pro-renin receptors (PRR) in the initiation and development of cancers. PRR is a component of the local renin-angiotensin system (RAS). Local tissue RAS has been known in diverse organ systems, including the pancreas. Various investigations have implicated that PRRs are associated with the upregulation of various signaling pathways, like the renin-angiotensin system pathway, PI3K/Akt/mTOR, and the Wnt-signaling pathways, to contribute to pathological conditions, including cancer. In this review, we presented an overview of the role of PRR in the progression of pancreatic adenocarcinoma

Cite this article as:

Aliakbarian Mohsen, Ferns Gordon A., Mohamadzadeh Shabestari Mahmoud, Ahmadzadeh Amir Mahmoud, Abdollahzade Aref, Rahimi Hoda, Khodashahi Rozita and Arjmand Mohammad-Hassan*, Elucidating the Role of Pro-renin Receptors in Pancreatic Ductal Adenocarcinoma Progression: A Novel Therapeutic Target in Cancer Therapy, Current Cancer Drug Targets 2024; 24 () . https://dx.doi.org/10.2174/0115680096279288231205105904